Insmed (INSM) shares are in focus after the company reported 12-month data from its ongoing open-label extension study of treprostinil palmitil inhalation powder in pulmonary arterial hypertension.

The TPIP update lands after a mixed period for Insmed, with the share price at $108.32. A 1-month share price return of 13.07% contrasts with a decline of 38.84% year to date, while the 3-year total shareholder return is very large, suggesting longer term momentum from earlier stages of the story even as short term sentiment has cooled.

If TPIP's progress has you thinking more broadly about healthcare opportunities, it could be a useful moment to scan other potential treatments in development using the 39 healthcare AI stocks

Insmed now trades at a steep discount to both analyst targets and an estimated intrinsic value, even after the recent rebound. Is the market being sensibly cautious about execution risk, or overly pessimistic about the pipeline payoff?

Most Popular Narrative: 45.1% Undervalued

On the most followed narrative, Insmed's fair value of $197.14 sits well above the last close at $108.32, framing the current discount through an earnings and cash flow lens that uses a 7.17% discount rate.

The analysts have a consensus price target of $197.14 for Insmed based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $243.0, and the most bearish reporting a price target of just $140.0.

Want to see what is driving that gap between today’s Insmed share price and the narrative fair value? The narrative is based on expectations of rapid revenue expansion, a sharp swing from losses to profits, and a richer future earnings multiple than the sector usually carries.

Result: Fair Value of $197.14 (UNDERVALUED)

However, the Insmed narrative also hinges on timely FDA decisions for brensocatib and payer acceptance, as delays or tighter reimbursement could quickly challenge those fair value assumptions.

Another View: What Insmed's Sales Multiple Is Telling You

Insmed may look cheap against fair value models, yet its P/S ratio of 28.6x is much higher than both the US Biotechs industry at 11.3x and peer average at 6.5x, and still above a fair ratio of 19.7x. Is the real risk that expectations are already rich?

Next Steps

With sentiment on Insmed clearly split between caution and optimism, now is the time to review the data first hand and decide where you stand. Then weigh both sides of the story by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insmed?

If the Insmed story has sharpened your focus, do not stop here. Use these targeted stock ideas to pressure test your thinking and avoid missing potential opportunities.

• Target potential mispricings by scanning for companies trading below estimated value using the 47 high quality undervalued stocks.
• Prioritise resilience by filtering for companies that pair low risk profiles with steady fundamentals through the 82 resilient stocks with low risk scores.
• Hunt for under-the-radar opportunities by reviewing a screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.